Rhythm Pharmaceuticals: New Approval Hype Masks Deep Losses and Execution Risks

What happened

Rhythm Pharmaceuticals' stock has surged 91% over the past year, driven by optimism around its hypothalamic obesity (HO) drug approval and expansion into rare MC4R-pathway obesities. Despite Q3 2025 revenue growing 54% year-over-year to $51.3 million, the company remains deeply unprofitable with a $149.0 million net loss for the first nine months of 2025 and ongoing cash burn. A recent article questions whether the stock is a buy after a new approval, noting its niche strategy differs from established weight-loss drug leaders. The DeepValue report rates RYTM as 'WAIT,' citing no margin of safety, a premium valuation embedding perfect HO execution, and risks from pricing pressures and trial failures. Critically, the company's reliance on external capital, crowded long positioning, and high SG&A growth signal elevated downside risk if the HO launch underperforms.

Implication

The stock's ~$105 price embeds flawless HO execution and pipeline wins, but with negative EBITDA and a price-to-book of 45x, any misstep could trigger sharp declines. External factors like reimbursement cuts in key markets add volatility, while the revenue-interest financing agreement limits financial flexibility and increases dilution risk. Monitoring early HO launch metrics, SG&A growth versus revenue, and cash runway over the next 6-12 months is crucial to assess if Rhythm can grow into its valuation. Persistent net losses and high operating expenses highlight the company's dependency on future catalysts, with no earnings-based safety net. Until clearer signs of operating leverage emerge, the risk-reward favors patience, with a more attractive entry potentially near $80.

Thesis delta

The new article's skepticism reinforces the DeepValue report's 'WAIT' rating, indicating no material shift in the investment thesis. Rhythm remains a high-risk story where current prices assume perfect execution, leaving investors exposed to significant downside if HO underperforms or expenses outpace growth.